Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Valero Energy Q4 Earnings Beat Expectations
Earnings call transcript: Landstar Q4 2024 misses EPS forecast, stock dips
Inc. reported its fourth-quarter 2024 earnings, revealing a slight miss on earnings per share (EPS) forecasts, which led to a negative market reaction. The company's EPS came in at $1.31, below the anticipated $1.
Tesla (TSLA) Q4 2024 earnings results miss EPS and revenue expectations
As one of the foremost electric vehicle companies in the world, Tesla continues to be an important company to watch in tech, but its Q4 2024 didn’t bring as good of news as investors might have expected. The company put out its latest earnings results, and with it came a miss on both revenue and earnings-per-share (EPS) versus analyst expectations.
Valero Energy Q4 Earnings Beat Expectations Despite Refining Woes: Details
Valero Energy Corporation (NYSE:VLO) reported a fourth-quarter sales decline of 13.2% year-on-year to $30.76 billion, beating the analyst consensus estimate of $30.20 billion. The Refining segment posted an operating income of $437 million,
Earnings call transcript: Littelfuse Q4 2024 misses EPS forecast, stock rises
Inc. reported its fourth-quarter 2024 earnings, revealing an adjusted diluted EPS of $2.14, which fell short of the forecasted $2.36. Despite this miss, the company's stock price increased by 2.63% in after-hours trading,
Novartis, Q4
Novartis handily beats Q4 earnings consensus
Novartis on Friday posted quarterly adjusted net income well above analyst estimates on forecast-beating sales of established heart failure drug Entresto and multiple sclerosis drug Kesimpta. Fourth-quarter net income,
Novartis reports Q4 core EPS $1.98 vs. $1.53 last year
Reports Q4 revenue $13.2B vs. $11.4B last year. Vas Narasimhan, CEO of Novartis (NVS), said: “In our first full year as a pure-play innovative
Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Novartis (NVS) reported $13.15 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 15.1%. EPS of $1.98 for the same period compares to $1.53 a year ago. The reported revenue represents a surprise of +1.
1d
on MSN
Roper Tops Q4 Revenue, EPS Estimates
Roper Technologies delivered strong fourth-quarter results exceeding market expectations, yet concerns linger about long-term ...
1d
Exxon Mobil Q4 Earnings: Mixed Results, But CEO Promises 'Profitable Growth Well Into the Future'
Exxon Mobil reported Q4 results with revenues of $83.4B, missing expectations. Adjusted EPS beat at $1.67 & company plans to ...
1d
Piper Sandler reports Q4 adjusted EPS $4.80, consensus $3.99
Reports Q4 revenue $485.38M, consensus $454.36M. “For 2024, we delivered a strong fourth quarter and our second strongest year on record with ...
2d
on MSN
MSCI's Q4 EPS Surpasses, Income Drops
Operating margins improved to 54.5%, supported by a vigilant control over expenditures, which grew by a modest 5.9%. Despite ...
1d
AbbVie Jumps After Q4 Earnings Beat, Skyrizi And Rinvoq Boom Offsets Humira Decline
AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue ...
19h
AbbVie Q4 Earnings: Strong Revenue Results, Ambitious Forecasts - A Buy With Caveats
AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.
1d
Northrop Grumman's Q4 Sales Stagnate, Space Systems Struggles, But Margins And EPS Improve
Northrop Grumman Corp (NYSE:NOC) reported fourth-quarter sales that were flat year over year at $10.686 billion, missing the ...
1d
on MSN
Nokia Delivers Strong EPS Growth in Q4
Nokia's earnings exceeded expectations despite a slight revenue miss.
20h
AbbVie Q4 Earnings: Good 2025 Outlook Despite Enhanced Old And New Headwinds
AbbVie reported strong Q4 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care. Click here to find out why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback